Literature DB >> 10364736

Plasma endothelin-1 level in chronic obstructive pulmonary disease: relationship with natriuretic peptide.

T Fujii1, T Otsuka, S Tanaka, H Kanazawa, K Hirata, M Kohno, N Kurihara, J Yoshikawa.   

Abstract

BACKGROUND AND
OBJECTIVE: Endothelin-1 (ET-1) is a potent vasoconstrictor peptide produced by the vascular endothelium. The purpose of this study was to elucidate the pathophysiological role of ET-1 in patients with pulmonary hypertension secondary to chronic obstructive pulmonary disease (COPD).
METHOD: We measured plasma ET-1 levels during right heart catheterization both at rest and during exercise on room air and while breathing oxygen in patients with COPD. In addition, we simultaneously measured plasma levels of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP).
RESULTS: Plasma ET-1 levels at rest were significantly higher in 21 patients with COPD than in 16 control subjects (p < 0.001). For COPD patients, there was no correlation between the plasma ET-1 level and pulmonary arterial pressure or pulmonary vascular resistance at rest. On the other hand, there was a significant negative correlation between plasma ET-1 level and mixed venous oxygen tension (r = -0. 503, p < 0.05). Also, the plasma ET-1 level was positively correlated with those of ANP (r = 0.540, p < 0.05) and BNP (r = 0. 533, p < 0.05) at baseline. Oxygen administration significantly decreased plasma ET-1 levels at rest (p < 0.05). Plasma ET-1 levels did not change significantly with exercise despite the progression of pulmonary hypertension and hypoxemia. In contrast, plasma ANP and BNP levels both increased markedly with exercise (p < 0.01).
CONCLUSION: We conclude that in patients with COPD, the plasma ET-1 level is not affected by acute progression of pulmonary hypertension and hypoxemia during exercise, and persistent hypoxemia may be associated with an increase in the plasma ET-1 level. In addition, our findings suggest that ANP and BNP may modulate the pulmonary vascular tone by interacting with ET-1 in these patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10364736     DOI: 10.1159/000029380

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  9 in total

1.  Controlled prospective randomised trial on the effects on pulmonary haemodynamics of the ambulatory long term use of nitric oxide and oxygen in patients with severe COPD.

Authors:  K Vonbank; R Ziesche; T W Higenbottam; L Stiebellehner; V Petkov; P Schenk; P Germann; L H Block
Journal:  Thorax       Date:  2003-04       Impact factor: 9.139

2.  Integrity of airway epithelium in pediatric burn autopsies: Association with age and extent of burn injury.

Authors:  Robert A Cox; Sam Jacob; Clark R Andersen; Ron Mlcak; Linda Sousse; Yong Zhu; Christopher Cotto; Celeste C Finnerty; Perenlei Enkhbaatar; David N Herndon; Hal K Hawkins
Journal:  Burns       Date:  2015-06-18       Impact factor: 2.744

3.  Vitamin B12 Supplementation and NT-proBNP Levels in COPD Patients: A Secondary Analysis of a Randomized and Controlled Study in Rehabilitation.

Authors:  Fernanda Viana Paulin; Leandro Steinhorst Goelzer; Paulo de Tarso Müller
Journal:  Front Neurosci       Date:  2020-07-14       Impact factor: 4.677

4.  Plasma C-reactive protein and endothelin-1 level in patients with chronic obstructive pulmonary disease and pulmonary hypertension.

Authors:  Yong Soo Kwon; Su Young Chi; Hong Joon Shin; Eun Young Kim; Byeong Kab Yoon; Hee Jung Ban; In Jae Oh; Kyu Sik Kim; Young Chul Kim; Sung Chul Lim
Journal:  J Korean Med Sci       Date:  2010-09-17       Impact factor: 2.153

5.  The role of endothelin-1 in hyperoxia-induced lung injury in mice.

Authors:  Walid Habre; Ferenc Peták; Isabelle Ruchonnet-Metrailler; Yves Donati; Jean-Francois Tolsa; Eniko Lele; Gergely Albu; Morice Beghetti; Constance Barazzone-Argiroffo
Journal:  Respir Res       Date:  2006-03-27

Review 6.  Role of endothelin-1 in lung disease.

Authors:  K A Fagan; I F McMurtry; D M Rodman
Journal:  Respir Res       Date:  2001-02-22

7.  Statins Have No Additional Benefit for Pulmonary Hypertension: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Lin Wang; Moying Qu; Yao Chen; Yaxiong Zhou; Zhi Wan
Journal:  PLoS One       Date:  2016-12-19       Impact factor: 3.240

Review 8.  B-type natriuretic peptides in chronic obstructive pulmonary disease: a systematic review.

Authors:  Nathaniel M Hawkins; Amit Khosla; Sean A Virani; John J V McMurray; J Mark FitzGerald
Journal:  BMC Pulm Med       Date:  2017-01-10       Impact factor: 3.317

9.  Antitussive activity of Pseudostellaria heterophylla (Miq.) Pax extracts and improvement in lung function via adjustment of multi-cytokine levels.

Authors:  Wensheng Pang; Siding Lin; Qiwen Dai; Hongcheng Zhang; Juan Hu
Journal:  Molecules       Date:  2011-04-19       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.